170 related articles for article (PubMed ID: 11180764)
1. Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer.
Tsuda H H
Breast Cancer; 2001; 8(1):38-44. PubMed ID: 11180764
[TBL] [Abstract][Full Text] [Related]
2. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
3. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
5. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
6. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
7. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
9. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.
Tapia C; Glatz K; Novotny H; Lugli A; Horcic M; Seemayer CA; Tornillo L; Terracciano L; Spichtin H; Mirlacher M; Simon R; Sauter G
Mod Pathol; 2007 Feb; 20(2):192-8. PubMed ID: 17361205
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.
Hoang MP; Sahin AA; Ordòñez NG; Sneige N
Am J Clin Pathol; 2000 Jun; 113(6):852-9. PubMed ID: 10874886
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.
Onody P; Bertrand F; Muzeau F; Bièche I; Lidereau R
Arch Pathol Lab Med; 2001 Jun; 125(6):746-50. PubMed ID: 11371225
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
13. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
14. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
15. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
Gu M; Ghafari S; Zhao M
Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
[TBL] [Abstract][Full Text] [Related]
17. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
19. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues.
Kobayashi M; Ooi A; Oda Y; Nakanishi I
Hum Pathol; 2002 Jan; 33(1):21-8. PubMed ID: 11823970
[TBL] [Abstract][Full Text] [Related]
20. The association of HER-2/neu amplification with breast cancer recurrence.
Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
